Teva announced the launch Abacavir and Lamivudine Tablets, the generic version of GlaxoSmithKline‘s Epzicom.

Abacavir and Lamivudine Tablets are indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection. They work to reduce the viral load and increase the number of CD4+ cells to help fight off other infections. 

Related Articles

Abacavir and Lamivudine are both nucleoside analogue HIV-1 reverse transcriptase inhibitors. Abacavir is converted by cellular enzymes to active metabolite CBV-TP, which inhibits the activity of  HIV-1 reverse transcriptase both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Lamivudine is phosphorylated into its active metabolite 3TC-TP, which inhibits reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue. 

Abacavir and Lamivudine Tablets are available as a 600mg/300mg strength in 30-count bottles. 

For more information call (888) 838-2872 or visit